Top

Category: Biotech


Biotech, Industry

Hunting a non-opioid painkiller, a biotech reveals plans to chase Vertex

February 14, 2024

Via: Biopharma Dive

A little over four years ago, biotechnology giant Amgen retreated from neuroscience research, halting much of its work developing treatments for diseases of the brain and trimming associated staff. Amgen’s pivot proved a boon for a small startup that was […]


Biotech, Industry

Alys launches with $100M and a pipeline of skin disease drugs

February 12, 2024

Via: Biopharma Dive

Six biotechnology startups are merging into a new skin drug developer called Alys Pharmaceuticals, which launched on Monday with $100 million from European life sciences investment firm Medicxi. Alys was formed out of the merger of a group of biotechs […]


Biotech, Industry

Arch, a prolific biotech creator, is raising $3B for startup investing

February 2, 2024

Via: Biopharma Dive

Arch Venture Partners, one of the biotechnology sector’s most prolific company creators, is raising a new $3 billion fund, according to a regulatory filing. The fund, which would be Arch’s 13th, is being put together less than two years after […]


Biotech, Industry

Synnovation’s $102m round heads latest biotech financings

January 26, 2024

Via: Pharmaphorum

Wilmington, Delaware-based Synnovation, a specialist in small-molecule therapeutics for cancer, has emerged from the shadows with a $102 million first-round financing led by Third Rock Ventures with participation from Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management. The […]


Biotech, Industry

CG Oncology prices larger-than-expected $380M IPO in hopeful sign for biotech

January 24, 2024

Via: Biopharma Dive

Cancer drug developer CG Oncology has raised $380 million in an initial public offering than was larger than it expected, a positive sign for a sector that’s struggled to generate demand from Wall Street investors recently. The company on Wednesday […]


Biotech, Industry

BridgeBio raises $1.25bn, and other biotech financings

January 19, 2024

Via: Pharmaphorum

Blue Owl Capital and Canada Pension Plan Investment Board have stepped in to bulk up cash reserves at BridgeBio as it prepares for the launch of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) and a market showdown with much larger rival […]


Biotech, Industry

A South Korean investment firm starts first US biotech fund

January 18, 2024

Via: Biopharma Dive

Mirae Asset Capital Life Science, a new venture capital fund, launched on Thursday, joining several other new firms that have recently emerged with plans to invest in drug startups. The fund is a spinout of Mirae Asset Financial Group, a […]


Biotech, Industry

Kyverna sets plans for IPO in test of biotech market

January 17, 2024

Via: Biopharma Dive

More than two years after the bottom fell out for biotech stocks, the market for IPOs is showing early signs of life, though investors are generally looking for more well-established companies than in the past. Four of the five companies […]


Biotech, Industry

AI Biotech Secures Funding to Speed Up Stem Cell Therapy Development

January 16, 2024

Via: Biopharm International

CellVoyant—an artificial intelligence (AI) first biotechnology company spun out of the University of Bristol—has raised £7.6 million in seed funding to speed up the development of novel cell therapies. According to a Jan. 16, 2024 press release, the funding was […]


Biotech, Industry

Newly optimistic, biotech investors weigh lessons of sector’s downturn

January 11, 2024

Via: Biopharma Dive

The J.P. Morgan Healthcare Conference, a yearly temperature taker for the biotechnology industry, had a different feel in 2024. For the first time in awhile, young drugmakers and their backers were optimistic the sector’s downturn might finally be over. An […]


Biotech, Industry

JPM: GSK announces $1.4bn deal to buy asthma biotech Aiolos

January 9, 2024

Via: Pharmaphorum

The deal – announced at the JP Morgan Healthcare conference this week – includes a sizeable $1 billion upfront payment, with up to $400 million more on the table if Aiolos’ pipeline delivers the results GSK is hoping for. AIO-001 […]


Biotech, Industry

Flagship outlines plans to raise $3B for new fund

November 30, 2023

Via: Biopharma Dive

Flagship Pioneering is looking to raise $3 billion for its eighth venture fund, a sign the high-profile company creator continues to see investor interest in the biotechnology sector despite a turbulent market. The plans were outlined in a securities document […]


Biotech, Industry

A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s

October 30, 2023

Via: Biopharma Dive

For years, many of the world’s largest, most deep-pocketed pharmaceutical firms had cast brain drugs aside, opting instead to devote resources to less risky, often more lucrative areas of research like oncology and immunology. But recent scientific and technological breakthroughs, […]


Biotech, Industry

Lessons from a biotech downturn: Funding challenges, an IPO dry spell and what to expect in 2024

October 26, 2023

Via: Biopharma Dive

Despite optimism for a stronger investment climate this year, many of the hurdles that faced young biotechnology companies in late 2022 have endured through 2023. Initial public offerings for drugmakers have remained slow, with only 18 biotechs making their public […]


Biotech, Industry

An Orbimed-backed biotech launches with $85M and plans for a new kind of DNA medicine

October 24, 2023

Via: Biopharma Dive

When developing new medicines, drugmakers typically try to make treatments that are more effective, durable or safer than what’s already available. If they’re lucky, they can hit on something that meets at least one of those goals. Rampart Bioscience, a […]


Biotech, Industry

How biotech IPOs performed in the third quarter

October 3, 2023

Via: Biopharma Dive

Initial public offerings may slowly be coming back to the biotechnology sector. Eight biotech companies priced IPOs from July through the end of September, raising $1.1 billion in total, according to data compiled by BioPharma Dive. That compares to four […]


Biotech, Industry

Seagen partners with Nurix to create new kind of cancer drug

September 7, 2023

Via: Biopharma Dive

Seagen is the biotech sector’s leading developer of antibody-drug conjugates, which deliver cell-killing toxins to diseased cells by attaching them to an antibody that seeks out proteins on tumor cells. Its first, Adcetris, is on track to become a blockbuster […]


Biotech, Industry

A biotech scraps two cancer trials in latest setback for emerging drug class

August 11, 2023

Via: Biopharma Dive

The success of cancer immunotherapies like Merck & Co.’s Keytruda and Bristol Myers’ Opdivo kicked off a broad search by biopharmaceutical companies for other ways to turn the immune system against cancer. One strategy that drew interest was targeting a […]


Biotech, Industry

Early-stage biotech funding on pace to drop 40% in 2023, HSBC report shows

July 29, 2023

Via: Biopharma Dive

Investors are much more cautious about the biotechs they back than they were during the sector’s peak a few years ago. Gone are the days when biotechs could easily raise cash and quickly pivot to public markets before starting a […]


Biotech, Industry

Merck’s New Jersey campus is getting a biotech makeover

July 11, 2023

Via: Biopharma Dive

While much of corporate America rethinks its investment in physical offices, biotechnology companies are still wedded to laboratories and research facilities. Onyx Equities, which earlier this year bought Merck & Co.’s former Kenilworth, New Jersey headquarters, is counting on that […]